Some areas of AAO.org are temporarily unavailable. We apologize for the inconvenience and are working to restore access.

  • Treating Exudative AMD With Bevacizumab Is Highly Cost-Effective

    Written By: Lynda Seminara
    Selected By: Richard K. Parrish II, MD

    In a cost analysis of bevacizumab, ranibizumab, and aflibercept, Roseneld et al. estimated the relative savings associated with bevacizumab in the treatment of exudative age-related macular degeneration in the United States.